

# OVERVIEW

MESOTRIONE (ZA1296)

11/18/2000

Study Type: Non-Guideline; Effects of AMBA (a Mesotrione Metabolite) on HPPD activity

Work Assignment No. 2-01-52M (amend 1) (MRID 44901711)

Prepared for

Health Effects Division  
Office of Pesticide Programs  
U.S. Environmental Protection Agency  
1921 Jefferson Davis Highway  
Arlington, VA 22202

Prepared by

Pesticides Health Effects Group  
Sciences Division  
Dynamac Corporation  
2275 Research Boulevard  
Rockville, MD 20850-3268

Primary Reviewer:  
Mary L. Menetrez, Ph.D.

Signature: Mary L Menetrez  
Date: 3/31/00

Secondary Reviewer  
Guy Beretich, Ph.D.

Signature: Guy Beretich  
Date: 4/3/00

Program Manager  
~~Mary L. Menetrez, Ph.D.~~

Signature: Mary L Menetrez  
Date: 4/1/00

Quality Assurance:  
Steve Brecher, Ph.D.

Signature: Steve Brecher  
Date: 4/3/00

## Disclaimer

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to signing by Dynamac Corporation personnel.

1  
SDB

AMBA (mesotrione metabolite)

Effect on HPPD activity (non-GDL)

EPA Reviewer: P. V. Shah, Ph.D  
Registration Action Branch 1/HED (7509C)

P.V. Shah

Work Assignment Manager: Marion Copley, DVM, DABT  
Registration Action Branch 1/HED (7509C)

Marion Copley 7/18/2000

OVERVIEW

STUDY TYPE: Effect on HPPD activity

OPPTS Number: N/A

OPP Guideline Number: non-GDL

DP BARCODE: D259369

P.C. CODE: 122990

SUBMISSION CODE: S541375

TOX. CHEM. NO.: None

TEST MATERIAL (PURITY): AMBA (mesotrione metabolite; 99% purity)

SYNONYMS: 2-amino-4-methylsulphonyl benzoic acid

CITATION: Elcombe, B. M., Meadowcroft, S., (1998) ZA1296: Effects of AMBA, a Metabolite of ZA1296 on p-Hydroxyphenylpyruvate Dioxygenase (HPPD) Activity. Central Toxicology Laboratory, Cheshire, UK, Laboratory Report No: CTL/R/1361; Study No: XR6243, April 1998. MRID 44901711. Unpublished.

SPONSOR: Zeneca AG Products, Wilmington, Delaware

Executive Summary: The objective of this study (MRID 44901711) was to investigate the inhibition of p-hydroxyphenylpyruvate dioxygenase (HPPD) by AMBA (a mesotrione metabolite; 99% purity, Y09476/001/001) in isolated liver cytosol from untreated male Alpk:Ap<sub>1</sub>SD rats. HPPD is involved in the catabolism of tyrosine by catalyzing the oxidative decarboxylation and rearrangement of 4-hydroxyphenylpyruvate (HPPA) to homogentisate. The liver cytosol samples were incubated with (i) AMBA at concentrations of 0.02 or 20 μM, (ii) mesotrione (96.8% purity, batch P17) and NTBC (92% purity) each at concentrations of 0.02, 0.2, or 20 μM (positive controls), and (iii) sodium phosphate buffer only (negative control). To assay HPPD activity, oxygen consumption rates (μL O<sub>2</sub>/min) for background, control (negative and positive), and treated liver cytosol samples were calculated.

The results of this special study are presented as an attachment to this overview (study report Tables 1 and 2, page 15). The addition of AMBA at 0.02 and 20 μM to isolated rat liver cytosol resulted in 0 and 18.7% inhibition of HPPD, respectively. The addition of mesotrione or NTBC at 0.02 μM resulted in 70-78% inhibition of HPPD, while concentrations of 0.2 and 20 μM resulted in 99-100% inhibition. The Sponsor stated that structure-activity relationships also indicated that the metabolite would be a weak inhibitor of HPPD.

In conclusion, AMBA is a weak inhibitor of HPPD *in vitro* and it appears it will not perturb tyrosine catabolism *in vivo*. A more definite conclusion cannot be reached without knowing the expected *in vivo* concentration.

ATTACHMENT

THE FOLLOWING ATTACHMENT IS NOT AVAILABLE ELECTRONICALLY  
SEE THE FILE COPY

---

Page 5 is not included in this copy.

Pages \_\_\_\_\_ through \_\_\_\_\_ are not included in this copy.

---

The material not included contains the following type of information:

\_\_\_\_\_ Identity of product inert ingredients.

\_\_\_\_\_ Identity of product impurities.

\_\_\_\_\_ Description of the product manufacturing process.

\_\_\_\_\_ Description of quality control procedures.

\_\_\_\_\_ Identity of the source of product ingredients.

\_\_\_\_\_ Sales or other commercial/financial information.

\_\_\_\_\_ A draft product label.

\_\_\_\_\_ The product confidential statement of formula.

\_\_\_\_\_ Information about a pending registration action.

~~\_\_\_\_\_~~ FIFRA registration data.

\_\_\_\_\_ The document is a duplicate of page(s) \_\_\_\_\_.

\_\_\_\_\_ The document is not responsive to the request.

---

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.

---